An estimated 500,000 people are affected by postpartum depression each year.
The first pill approved to treat postpartum depression will be priced at $15,900 for a two-week treatment course, its manufacturer said.since the FDA in August approved Sage Therapeutics and Biogen's drug, Zurzuvae, for just postpartum depression and not major depressive disorder.
The launch price was above RBC Capital's estimate of $11,000, per a note from senior analyst Brian Abrahams. Though Abrahams noted initial uncertainty about the drug's market size and how insurers may cover it, he predicted a modest launch after the drug starts becoming available in December.Share on linkedin
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
First-ever Fortune 500 Europe list launches, Mercedes-Benz ranked among top 10Ordering the region's largest operations by total revenue, the debut arrives as the American business magazine extends its editorial purview online.
Read more »
Accused mastermind of elaborate $15 million 'warranty deed scam' arrested by Precinct 1 deputiesJeanette Clifton, 18, Serenity Delgado, 17, and Cruz Martinez, 18, are accused in the shooting death of Nathaniel Navarro at Satsuma Park.
Read more »
Man accused in $15 million warranty deed scam in Harris County facing multiple chargesHarris County deputies said the man would forge property owners' signatures on their warranty deeds and purchase their property at a drastically undervalued price.
Read more »
SpaceX eyes $15 billion in 2024 sales on Starlink strengthInternal SpaceX data shows growth of the Starlink satellite business, with 2023 revenue expected to hit $9 billion from rocket launches and Starlink.
Read more »
Markets Poised to End the Year With a RallyMarket Overview Analysis by Brad McMillan covering: S&P 500, iShares Core S&P 500 ETF, SPDR® S&P 500, S&P 500 Futures. Read Brad McMillan 's latest article on Investing.com
Read more »